Sign in
CompletedPhase 3

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Key facts

Who runs it
Axsome Therapeutics, Inc.
Where
Austin, Bellaire, Berlin, Boston, Cherry Hill, Cincinnati, Clermont, Colorado Springs, Dallas, Doral, Draper, Encino, Everett, Gainesville, Garden Grove, Jacksonville, Kettering, Las Vegas, Lauderhill, Lincoln, Marietta, Media, Memphis, Miami Lakes, Mount Kisco, New York, Newport Beach, North Charleston, Oklahoma City, Orlando, Overland Park, Princeton, Raleigh, Riverside, Saint Charles, San Antonio, Santa Ana, Sherman Oaks, Torrance, and Walnut Creek, United StatesSee the 40 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
516 people enrolled
Started
6 Jul 2023
Ended
14 Mar 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Solriamfetol 150 mg
  • Solriamfetol 300 mg
  • Placebo
Record updated
10 February 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Primary diagnosis of ADHD according to DSM-5 criteria
  • Provides written informed consent to participate in the study before the conduct of any study procedures
  • Male or female, aged 18 to 55 inclusive

Who cannot take part

  • Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription
  • Unable to comply with study procedures
  • Medically inappropriate for study participation in the opinion of the investigator

Where in United States

  • Austin, TexasHospital not named in the registry
  • Bellaire, TexasHospital not named in the registry
  • Berlin, New JerseyHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Cherry Hill, New JerseyHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Clermont, FloridaHospital not named in the registry
  • Colorado Springs, ColoradoHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Doral, FloridaHospital not named in the registry
  • Draper, UtahHospital not named in the registry
  • Encino, CaliforniaHospital not named in the registry
  • Everett, WashingtonHospital not named in the registry
  • Gainesville, GeorgiaHospital not named in the registry
  • Garden Grove, CaliforniaHospital not named in the registry
  • Jacksonville, FloridaHospital not named in the registry
  • Kettering, OhioHospital not named in the registry
  • Las Vegas, NevadaHospital not named in the registry
  • Lauderhill, FloridaHospital not named in the registry
  • Lincoln, NebraskaHospital not named in the registry
  • Marietta, GeorgiaHospital not named in the registry
  • Media, PennsylvaniaHospital not named in the registry
  • Memphis, TennesseeHospital not named in the registry
  • Miami Lakes, FloridaHospital not named in the registry
  • Mount Kisco, New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • Newport Beach, CaliforniaHospital not named in the registry
  • North Charleston, South CarolinaHospital not named in the registry
  • Oklahoma City, OklahomaHospital not named in the registry
  • Orlando, FloridaHospital not named in the registry
  • Overland Park, KansasHospital not named in the registry
  • Princeton, New JerseyHospital not named in the registry
  • Raleigh, North CarolinaHospital not named in the registry
  • Riverside, CaliforniaHospital not named in the registry
  • Saint Charles, MissouriHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Santa Ana, CaliforniaHospital not named in the registry
  • Sherman Oaks, CaliforniaHospital not named in the registry
  • Torrance, CaliforniaHospital not named in the registry
  • Walnut Creek, CaliforniaHospital not named in the registry

About the trial

What the trial wants to find out

FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

The 3 groups in the trial

  • Solriamfetol 150 mgTreatment being tested

    Up to 6 weeks

  • Solriamfetol 300 mgTreatment being tested

    Up to 6 weeks

  • PlaceboPlacebo, for comparison

    Up to 6 weeks

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults With ADHD.
Publications
Record updated
10 February 2026